P

Precision AQ

Data-driven drug access and launches

Executive Director/Site Head

Full-Time
$203.2k - $304.8k+ Discretionary annual bonus
Expert
PhD
Frederick, MD, USA
In Person
Biology & Biotech
No H1B Sponsorship

About the job

Requirements
  • A PhD in Immunology or a related field is required.
  • At least 20 years of relevant experience is required.
  • At least 15 years of leadership experience is required.
  • Prior supervisory experience is required.
  • Direct working experience and knowledge in cell-based assays and bioanalysis of large or small molecules used to support clinical studies is required.
  • A solid understanding of current GLP, GCP, or GCLP standards is required.
  • Working knowledge of CAP/CLIA, CLSI, and ISO 13485 is required.
  • Experience hosting and participating in regulatory audits is required.
  • Proficiency with Microsoft Word, Excel, and PowerPoint is required.
  • Must be able to read, write, speak fluently, and comprehend English.
  • Must be legally authorized to work in the country of employment without employer sponsorship.
Responsibilities
  • Oversee operational aspects of all laboratories in Frederick, including Bioanalysis, Flow Cytometry, and Companion Diagnostic.
  • Support, hire, coach, and mentor laboratory heads in Bioanalytical, Flow, and CDx.
  • Collaborate with site-supporting departments, including Facilities, Biorepository, Quality Assurance, and Finance, as well as other global site heads.
  • Monitor and report site KPIs, including quality events, turnaround time, capacity, revenue delivery, and budget adherence.
  • Improve operations and enhance operational excellence in each laboratory.
  • Provide weekly and monthly revenue reporting, cost tracking, and margin expansion.
  • Provide operational excellence leadership to ensure the team is efficient and appropriately resourced.
  • Mentor and lead laboratory heads for all applicable laboratories.
  • Direct staff to ensure consistent scientific standards and compliance with company procedures and regulatory expectations on all projects.
  • Ensure all work complies with applicable regulatory guidelines, including CAP, CLIA, and GxP.
  • Work with Quality Assurance and the regulatory team to ensure compliance with industry standards.
  • Attend and participate in FDA calls regarding assay development and compliance.
  • Ensure development and validation study protocols and reports meet CAP/CLIA and CLSI requirements.
  • Establish and implement a communication strategy for timely and consistent dissemination of information to stakeholders across the site and within the company.
  • Communicate with clients, manage client expectations for team projects, and serve as a client escalation point.
  • Establish best practices for company business operations processes and systems to support growth and efficiency.
  • Prepare and review protocols, reports, and SOPs; oversee the establishment and improvement of procedures and required SOP documentation.
  • Oversee troubleshooting and resolution of scientific issues within the teams.
  • Support leaders in reviewing data and provide written and verbal technical updates to clients as needed.
  • Collaborate with other technical teams on resource sharing and provide technical expertise.
  • Serve as a scientific resource for clients and internally on Product and Services/R&D-related projects.
  • Assist with writing, reviewing, and editing contracts, scopes of work, and change orders.
  • Maintain and support safe laboratory practices and environments.
  • Carry out other assigned duties and projects.
Desired Qualifications
  • Direct experience working at a CRO, biotechnology, or pharmaceutical company is preferred.
  • Expertise across multiple technology platforms, including ECL, ligand-binding assays (LBA), cell-based plate assays, flow cytometry, and enzymatic activity assays, is preferred.

About the company

Precision AQ helps pharmaceutical companies get FDA-approved medicines to patients by using data, evidence, and market insights to shape access and launches. Its services combine medical science, commercial strategy, and technology development to create new pathways for drug availability and timely delivery. The company partners with drug makers to plan launches and expansion, using analytical and creative approaches to make medicines reachable and effective in real-world settings. Unlike firms that focus only on science or marketing, Precision AQ blends data-driven insights with strategic execution across development and commercialization to accelerate patient access. The goal is to raise standards in healthcare accessibility and impact by getting the right medicines to the right patients faster.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

New York City, New York

Founded

N/A

Get referred to Precision AQ

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • February 17, 2026 hires Yahya Anvar and Emma Hawe deepen AI and HTA capabilities.
  • August 12, 2026 Candice Subero hire boosts marketing-led customer engagement and commercial growth.
  • Precision AQ’s 2025 Phluence investment advances agentic patient solutions, reducing post-Rx service costs.

What critics are saying

  • Precision AQ reported $314.5 million revenue in 2024, down 7%, signaling slower growth.
  • Phluence integration in November 2025 risks distracting teams while AI patient-service economics remain unproven.
  • If pharma shifts to in-house AI access tools, Precision AQ’s HUB model weakens.

What makes Precision AQ unique

  • Precision AQ works with all top 30 pharma companies and 350+ active engagements in 2026.
  • Its 2024 rebrand unified pricing, HEOR, medical affairs, and omnichannel capabilities under one platform.
  • Precision AQ has launched over 450 drugs, creating embedded launch expertise across therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Life Insurance
  • Disability Insurance
  • Paid Vacation
  • Paid Sick Leave
  • Parental Leave
  • Performance Bonus

Company News

PR Newswire
Feb 17th, 2026
Precision AQ expands leadership with AI and data strategy hires to strengthen global biopharma solutions

Precision AQ, a global life sciences commercialisation partner, has appointed two senior leaders to expand its AI and data capabilities. Emma Hawe joins as Senior Vice President, Managing Director for Evidence Synthesis & Decision Modelling, bringing over 25 years of experience in evidence generation and applied statistics. She currently chairs ISPOR's HEOR Excellence—Methodology Award. Yahya Shaikh becomes Senior Vice President, Data Strategy & AI, focusing on strengthening the company's data foundation and advancing AI-enabled solutions. He brings decades of experience in AI, analytics and enterprise data strategy across life sciences and healthcare. The appointments aim to bolster Precision AQ's presence in the EU whilst expanding its global reach. The company works with all 30 top pharmaceutical firms and has launched over 450 drugs across therapeutic areas.

StreetInsider
Nov 18th, 2025
Precision AQ Invests in Phluence Platform

Precision AQ has made a strategic investment in Phluence, enhancing its post-prescription capabilities. This investment allows pharmaceutical manufacturers to virtualize patient services, reduce costs, and improve access through Phluence's advanced agentic workflow management platform. The collaboration aims to modernize patient engagement with AI-driven solutions, offering an alternative to traditional HUB models. This move supports Precision AQ's goal to streamline patient services and accelerate access to therapies.

PR Newswire
Apr 25th, 2025
Precision Aq Expands Industry-Leading Access Experience Team (Aet) With Three Oncology Experts

-- Shraddha Kansagra, PharmD, BCOP, former Clinical Pharmacy Specialist at UT Southwestern, appointed Vice President, Clinical Oncology Solutions ---- Angelica Norrell, PharmD, BCOP, CSP, former Senior Director of Product at Optum, joins as Senior Director, AET ---- Courtney Patterson, PharmD, MBA, former System Director of Oncology Pharmacy Services at Advocate Health, joins as Vice President, Clinical Oncology Solutions --NEW YORK, April 25, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the additions of Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA to its Access Experience Team (AET). These experts join Precision AQ's AET, an industry-leading team of former access decision-makers and influencers, to provide critical insights to life science companies and support them in anticipating payer challenges and designing strategies to optimize patient access in oncology.As access decisions in oncology increasingly incorporate both payer and provider perspectives, the additions of Drs. Kansagra, Norrell, and Patterson reflect Precision AQ's commitment to evolving with the landscape. Precision AQ's AET boasts numerous oncology experts, including five Board Certified Oncology Pharmacists (BCOPs), from prominent payer and provider-based institutions across the United States. These new additions further bolster the AET's expertise and capabilities, including driving medical and pharmacy benefit management for Value Based Care, drug coverage policy and formulary design; optimizing patient care through quality improvement initiatives; and overseeing pharmacy and healthcare operations."We are delighted to welcome Shraddha, Angie, and Courtney to Precision AQ, bolstering our AET with additional expertise in oncology, one of the most innovative areas in healthcare," said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. "Together with our existing roster of top-tier access decision makers, as well as our external network of over 100 oncology advisors from leading U.S

PR Newswire
Mar 31st, 2025
Precision Aq Earns Hitrust Implemented, 1-Year I1 Certification For Data Protection And Cybersecurity Risk Management

HITRUST i1 certification confirms Precision AQ's commitment to protecting sensitive data with leading security practices.NEW YORK, March 31, 2025 /PRNewswire/ -- Precision AQ, a leader in guiding life science organizations through the complexities of product commercialization and empowering access to life-changing medicines for all, announced today that its PatientLens platform has achieved HITRUST certification for system and information security.PatientLens transforms healthcare insights and patient program design by reducing friction in patient services and by delivering timely, actionable information to support decision-making. The platform offers a detailed view of insurance coverage, out-of-pocket costs, and medical or medication history. By leveraging tokenized patient data and advanced analytics, PatientLens helps healthcare organizations optimize patient outreach, prioritize cases, and ensure compliance, driving improved outcomes and operational efficiency.The HITRUST Implemented, 1-Year i1 validated assessment and certification process confirms that the PatientLens platform applies a robust set of HITRUST-curated controls. These controls ensure the organization follows leading security practices and maintains a comprehensive cybersecurity program to defend against cyber threats. HITRUST continuously analyzes cyber threat intelligence to keep its control requirements relevant, helping organizations mitigate emerging risks like phishing, brute force attacks, and ransomware, and supporting organizational resilience."The HITRUST i1 validated assessment is a powerful tool for cyber-aware organizations, such as Precision AQ," said Robert Booker, Chief Strategy Officer at HITRUST. "This certification assures the measurement, implementation, and performance of robust information security controls

GlobeNewswire
Mar 4th, 2025
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...